此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Rapid Construction of Tissue-engineered Skin for Repairing Difficult-to-heal Wounds

2026年4月27日 更新者:Hu Zhicheng、First Affiliated Hospital, Sun Yat-Sen University

Rapid Construction of Tissue-engineered Skin for Repairing Difficult-to-heal Wounds: A Multicenter Real-world Study

This multicenter real-world study evaluates the efficacy and safety of a novel technique for rapid intraoperative construction of tissue-engineered skin using autologous epidermal stem cells (EpiSCs) for repairing difficult-to-heal wounds. Eligible patients are randomized to receive either: (1) the experimental intervention (rapidly constructed EpiSCs-loaded scaffold combined with split-thickness skin graft via one-step or two-step procedure), or (2) control intervention (acellular scaffold combined with split-thickness skin graft). The primary outcome is the complete wound healing rate at 4 weeks post-surgery. Secondary outcomes include wound recurrence, scar quality (VSS/POSAS), functional recovery (sweat test), mortality, amputation rate, and safety profile.

研究概览

研究类型

介入性

注册 (估计的)

1000

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Guangdong
      • Guangzhou、Guangdong、中国
        • 招聘中
        • The First Affiliated Hospital of Sun Yat-sen University
        • 接触:
          • The First Affiliated Hospital of Sun Yat-sen University
          • 电话号码:87755766-8265
          • 邮箱:huzhch5@mail.sysu.edu.cn

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • All-age population

Wounds requiring surgical repair (single area 10-100 cm²): acute wounds (burns, traumatic defects, post-scar resection) OR chronic wounds (diabetic foot ulcers, pressure injuries, vascular ulcers)

Completed wound bed preparation (no necrotic tissue, infection controlled)

Signed informed consent and agreement to use tissue-engineered materials and long-term follow-up

Exclusion Criteria:

  • History of allergy to allogeneic/xenogeneic tissue-engineered scaffolds or collagen materials

Severe immunosuppression (HIV/AIDS, long-term immunosuppressant use)

Malignant tumors, uncontrolled systemic infection (CRP > 50 mg/L), or organ failure (Child-Pugh Class C)

Mental illness preventing compliance with treatment or follow-up

Pregnant or lactating women

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Rapid Tissue-Engineered Skin Group
Rapid intraoperative construction of autologous EpiSCs-loaded scaffold + split-thickness skin graft (one-step or two-step procedure)
Autologous split-thickness skin (0.15-0.2 mm) is harvested from the donor site at a donor-to-wound area ratio of 1:20-30. The harvested skin is processed using a specialized cell sorter to isolate autologous epidermal stem cells (EpiSCs) with >93% viability within 30 minutes. The cell suspension is adjusted to a concentration of ≥1×10⁶ cells/mL and loaded onto a tissue-engineered scaffold via spraying or immersion (3-5 minutes). The cell-seeded scaffold is then applied to the wound bed. Depending on wound condition: (1) One-step procedure: scaffold and a split-thickness skin graft (0.15-0.2 mm) are applied simultaneously; (2) Two-step procedure: scaffold is implanted first, followed by split-thickness skin graft at 14±3 days post-primary surgery. Negative pressure wound therapy (-100 to -125 mmHg) is applied as needed.
有源比较器:Traditional Composite Skin Graft Group
The same tissue-engineered scaffold (without cell loading) is used. Autologous split-thickness skin graft (0.15-0.2 mm thickness) is harvested. The acellular scaffold is applied to the debrided wound bed followed by coverage with the split-thickness skin graft. The surgical procedure, postoperative wound care, negative pressure wound therapy (-100 to -125 mmHg when indicated), and follow-up protocol are identical to those in the experimental arm. This comparator represents the current standard of care for composite skin grafting in the participating centers.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Complete Wound Healing Rate
大体时间:At 4 weeks post-surgery
The percentage of participants achieving complete wound epithelialization (defined as 100% re-epithelialization without drainage or dressing requirements)
At 4 weeks post-surgery

次要结果测量

结果测量
措施说明
大体时间
Wound Recurrence Rate
大体时间:3, 6, 12 months post-surgery
Incidence of wound recurrence at the healed site
3, 6, 12 months post-surgery
Scar Quality Assessment
大体时间:4 weeks, 3, 6, 12 months post-surgery
Scar quality is assessed using the Vancouver Scar Scale (VSS) and the Patient and Observer Scar Assessment Scale (POSAS) at 4 weeks, 3, 6, and 12 months post-surgery. The VSS total score ranges from 0 to 13, with higher scores indicating worse scar outcome (assessing vascularity, pigmentation, pliability, and height). The POSAS includes two separate subscales: the Observer Scale (6 items, each scored 1 to 10, total range 6-60) and the Patient Scale (6 items, each scored 1 to 10, total range 6-60). For both POSAS subscales, higher scores represent worse scar outcome.
4 weeks, 3, 6, 12 months post-surgery
Functional Recovery
大体时间:6, 12 months post-surgery
Sweat test for assessment of sweat gland regeneration
6, 12 months post-surgery
Mortality Rate
大体时间:3, 6, 12 months post-surgery
All-cause mortality
3, 6, 12 months post-surgery
Amputation Rate
大体时间:3, 6, 12 months post-surgery
Incidence of amputation (for chronic wound patients)
3, 6, 12 months post-surgery
Healing Trajectory
大体时间:1, 2, 3 weeks post-surgery
Wound healing rate at week 1, 2, 3; and time to complete healing
1, 2, 3 weeks post-surgery
Safety Outcome
大体时间:From day of surgery through 12 months post-surgery
Safety outcome is the incidence of postoperative complications (including infection, hematoma, and graft failure), adverse events, and serious adverse events, assessed from the day of surgery through study completion, an average of 12 months.
From day of surgery through 12 months post-surgery

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年1月1日

初级完成 (估计的)

2029年12月31日

研究完成 (估计的)

2030年12月1日

研究注册日期

首次提交

2026年4月14日

首先提交符合 QC 标准的

2026年4月27日

首次发布 (实际的)

2026年5月1日

研究记录更新

最后更新发布 (实际的)

2026年5月1日

上次提交的符合 QC 标准的更新

2026年4月27日

最后验证

2026年4月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 2026P-ZD025

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅